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Summary
Background About 3·7 billion doses of ivermectin have been distributed in mass drug administration (MDA) 
campaigns globally over the past 30 years. At 10–100 times higher than current human doses, ivermectin is a known 
teratogen in mammals. During these campaigns with recommended doses, pregnant women might be inadvertently 
exposed. We therefore aimed to evaluate the existing evidence for serious and non-serious adverse events after 
ivermectin exposure in pregnant women.
Methods For this systematic review and meta-analysis, we searched relevant databases and trial registry platforms on 
July 15, 2018, for randomised controlled trials (RCTs) and observational studies that reported adverse events in 
pregnant women. We did not use language or date restrictions. Outcomes of interest were spontaneous abortions, 
stillbirths, congenital anomalies, and neonatal death (serious adverse events), as well as maternal morbidity, preterm 
births, and low birthweight (adverse events). The risk of bias was assessed using the Newcastle-Ottawa Scale for 
observational studies and the Cochrane Risk of Bias Tool for RCTs. We did the meta-analysis of observational studies 
and RCTs separately. The quality of evidence was assessed using the GRADE approach. The study protocol is 
registered with PROSPERO, protocol CRD42016046914.
Findings We identified 147 records, of which only five observational studies and one RCT were included for quantitative 
analysis; these studies were published between 1990 and 2008, and were done in six African countries. 893 women 
with 899 pregancy outcomes were included, of whom 496 pregnant women (500 pregnancy outcomes) received 
ivermectin inadvertently during MDA campaigns in the observational studies and 397 pregnant women (399 pregnancy 
outcomes) purposely received ivermectin as part of the open-label RCT. No study reported neonatal deaths, maternal 
morbidity, preterm births, or low birthweight. It is unclear whether exposure to ivermectin during pregnancy 
increases the risk of spontaneous abortions and stillbirths (odds ratio [OR] 1·15 [95% CI 0·75–1·78] with very low 
certainty of evidence for the four observational studies and 0·62 [0·18–2·14] with very low certainty of evidence for 
the RCT) or congenital anomalies (OR 1·69 [95% CI 0·83–3·41] with very low certainty of evidence for the 
five observational studies and 1·10 [0·07–17·65] with very low certainty of evidence for the RCT).
Interpretation There is insufficient evidence to conclude on the safety profile of ivermectin during pregnancy. 
Treatment campaigns should focus additional efforts on preventing inadvertent treatment of pregnant women.
Funding Unitaid.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Ivermectin is a widely used antiparasitic drug.1–3 Since 
1987, more than 3·7 billion treatments have been donated 
by Merck through the Mectizan Donation Programme 
with the goal of eliminating onchocerciasis. In 1998, this 
donation programme was expanded to include lymphatic 
filariasis.4,5 The global demand for ivermectin is expected 
to remain high because of its licensure for use against 
Strongyloides, scabies,3,6 the potential to eliminate lym­
phatic filariasis when given as part of a three­drug 
combination with albendazole and diethylcarbamazine,7 
combined regimens for soil­trans mitted helminths, and 
its potential role as an endectocide to reduce malaria 
transmission by killing malaria vectors.8
Before moving to the narrative description required 
by the 2015 labelling rule,9 the US Food and Drug 
Administration (FDA) had previously classified ivermectin 
as pregnancy category C—ie, “Animal reproduction 
studies have shown an adverse effect on the foetus and 
there are no adequate and well­controlled studies in 
humans, but potential benefits may warrant use of the 
drug in pregnant women despite potential risks”.1 This 
classification is based on studies done in mice, rats, and 
rabbits during the original New Drug Application in the 
1990s by Merck (appendix p 2).10 These studies showed 
adverse pregnancy outcomes at cumulative doses that are 
high enough to produce signs of maternal toxicity in 
animals, ranging between 20 and 600 times the human 
Mectizan single­dose target of 0·15–0·20 mg/kg. However, 
later evidence showed that the mouse strain (CF­1) used in 
the initial acute and developmental ivermectin toxicity 
studies was inappropriate, as it was later shown that CF­1 
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mice have deficient P­glycoprotein expression, which is 
an efflux pump key to preventing ivermectin toxicity.11
During ivermectin mass drug administrations (MDAs) 
for onchocerciasis and lymphatic filariasis, visibly and 
self­reported pregnant women are excluded from treat­
ment without requiring pregnancy testing.12 This 
omission of testing leads to an unknown number of 
women at risk of inadvertent exposure to ivermectin 
early in pregnancy, which could be as high as 50% of 
women in their first trimester.13 In highly endemic 
onchocerciasis areas, where risk of eyesight loss is high, 
Mectizan campaigns have included pregnant women at 
the discretion of the programme.12 Research done in 
the early days of ivermectin MDA for onchocerciasis14 
showed that simple questioning was the most efficient 
method to detect pregnancy in this context, although this 
point might require validation against newer, more 
sensitive tests. The programme’s decision was based on 
the large clinical experience of the campaigns, in which 
inadvertent use in hundreds of pregnant women had no 
apparent harmful effect. The decision was supported 
by evidence that P­glycoprotein in the placenta prevents 
avermectins (the drug family to which ivermectin 
belongs) from penetrating the placenta.11,12 P­glycoprotein 
also minimises ivermectin­induced neurotoxicity in 
mammals by active efflux of the drug at the blood–brain 
barrier, thus preventing ivermectin entry into the 
CNS.15 However, rat and human placental P­glycoprotein 
expression during gestation differ; in humans, placental 
P­glycoprotein expression wanes during gestation,16,17 
whereas it increases in rats.18 In general, human blood–
brain barrier development begins earlier in gesta tion and 
proceeds faster compared with rodents,19 with human 
blood–brain barrier P­glycoprotein detectable as early as 
8 weeks of gestation.20 Indeed, in humans, the expression 
of blood–brain barrier P­glycoprotein reaches far higher 
concentrations during gestation when compared with 
mice or rats.21–23
Weighing the risks and benefits of ivermectin use in 
pregnancy is imperative for informed public health 
policy (eg, MDA campaigns), as well as for individual 
treatment decisions. We therefore aimed to review and 
summarise all available safety data from controlled 
studies of the effect of ivermectin exposure in pregnancy 
to assist programmatic decision making and to better 
understand the implications of the use of ivermectin in 
pregnant women.
Methods
Search strategy and selection criteria
We did a systematic review and meta­analysis of 
ivermectin exposure during pregnancy. We searched 
MEDLINE, Scopus, Toxline, and the US FDA List of 
Pregnancy Exposure Registries on July 15, 2018. We did 
not use a language or date restriction. We also searched 
WHO’s International Clinical Trials Registry Platform, 
ClinicalTrials.gov, and the Cochrane Central Register of 
Controlled Trials, using the search terms “(ivermectin OR 
mectizan OR stromectol) AND pregnan*” and “(ivermectin 
OR mectizan OR stromectol) AND (abortion OR stillbirth 
OR malformation)”. The full search strategy is summa­
rised in the appendix (p 3).
We included randomised controlled trials (RCTs) and 
observational studies, including cohort studies and case­
control studies, that reported maternal or fetal serious and 
non­serious adverse events following oral administration 
of ivermectin to pregnant women at a dose of 150 μg/kg or 
more at any gestational timepoint. Background rates from 
pregnant women of the same or comparable population 
that had not received ivermectin (controls in cited studies) 
were used as a comparator (ie, the control group).
Expected serious adverse events in the context of this 
review included spontaneous abortions (death of the 
embryo or fetus before 28 weeks of gestation), stillbirths 
(the delivery of a baby that has died in the womb after at 
least 28 weeks of gestation), congenital anomalies, and 
See Online for appendix
Research in context
Evidence before this study
Ivermectin is one of the most broadly used drugs in global 
health. More than 3∙7 billion treatments have been safely 
distributed in the context of Merck’s donation programme. 
Pregnant women are usually excluded from treatment but no 
formal evaluation of the safety in pregnancy has been done to 
date. Additionally, no systematic reviews or meta-analyses of 
ivermectin exposure in pregnant women have been published 
according to our provisional literature search of MEDLINE, 
Scopus, and the Cochrane Library.
Added value of this study
Pregnant women are getting inadvertently exposed to 
ivermectin during mass drug administration campaigns. 
Weighing the risks and benefits of ivermectin in pregnancy is 
crucial for informed public health policies and for individual 
treatment decisions. In this systematic review and meta-analysis, 
we determined the odds ratio of adverse pregnancy outcomes 
after exposure to ivermectin during pregnancy compared with 
untreated pregnant women from matching populations in 
controlled studies. We identified an important evidence gap 
regarding the effect of ivermectin exposure in pregnancy.
Implications of all the available evidence
High-quality evidence supporting the safety of ivermectin 
administration in this vulnerable group is imperative. 
The existing data have been generated in studies not designed 
to determine the safety of ivermectin administration during 
pregnancy. Further steps for generating the necessary safety 
data should encompass an open data repository of inadvertent 
drug exposures during pregnancy among other potential 
readily available options.
For WHO’s International Clinical 
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neonatal death (the death of a baby before 28 days of age). 
Expected adverse events included maternal morbidity 
(weight loss, signs of ivermectin intoxication such as 
ataxia, tremor, and stupor), preterm births (delivery 
between 28 and 37 weeks resulting in a live baby), and 
low birthweight (term delivery of a baby weighing less 
than 2500 g).
Three review authors (WM, QB, and KCK) independently 
assessed the titles and abstracts of studies identified by 
the searches, and assessed the full­text copies for inclu­
sion using a pre­piloted electronic eligibility form. If 
extracted data differed, the three review authors discussed 
these differences and, if unable to resolve them, involved 
other review authors (PN, CC, and AB) to reach consensus. 
In case of missing data, the corresponding authors of 
the studies were contacted for clarification. Multiple 
publications of the same trial were only included once. 
The extracted data included the study design, the study 
settings and population characteristics, context of the 
administration (eg, MDA programme for neglected tropi­
cal diseases), whether administration was inadvertent or 
intentional, ivermectin dosage and regimen, coadmin­
istration with another drug, and estimated gestational age 
at administration. Data for the number and description of 
both serious adverse events and adverse events were 
extracted for each study as well as number of events for 
the intervention and control groups, and total number of 
participants.
Data analysis
The primary outcome measure was adverse pregnancy 
outcome (stillbirth, spontaneous abortions, or congenital 
malformations). A woman can have more than one 
outcome per pregnancy—ie, with multiple births or with 
stillbirth and  malformation in a singleton pregnancy 
Meta­analysis of the serious adverse events was done 
separately for observational studies and RCTs, and was 
stratified by the type of serious adverse event. The risk of 
serious adverse events occurring in pregnant women 
exposed and non­exposed to ivermectin was estimated 
using odds ratios (ORs) as a pooled measure of effect. 
Reasons for substantial heterogeneity were explored 
using subgroup analysis of studies that had admin­
istered ivermectin in combination with albendazole—
also a known teratogen in rats and rabbits and classified 
as FDA pregnancy category C24—which is common 
practice during lymphatic filariasis MDAs, and studies 
that had administered ivermectin alone. A random­
effects model was chosen given the nature of the 
outcome being a rare event. Forest plots were used 
to present the pooled ORs and 95% CIs. Statistical 
heterogeneity was assessed using I², which indicates the 
percentage of variation among the studies that occurs as 
a result of heterogeneity rather than chance. Variation 
across all studies was categorised as low (I² <25%), 
moderate (I² between 50% and 75%), high (I² >75%), or 
no statistical heterogeneity (I² = 0%).
Two review authors (PN and MFM) independently 
assessed the risk of bias for each included study using 
the Newcastle­Ottawa Scale for assessing the quality of 
observational studies.25 Risk of bias for RCTs was 
assessed using the Cochrane Risk of Bias Tool.26 The 
Newcastle­Ottawa Scale was used to evaluate the selec­
tion of participants, comparability of study groups, and 
the ascertainment of exposure or outcome of interest. 
The scale is grouped into three parts: selection (4 points), 
comparability (2 points), and outcome (3 points), for a 
maximum of 9 points. Studies scoring zero in any of the 
categories were classified as having high risk of bias. 
Studies scoring 1 point in any of the categories were 
classified as having moderate risk of bias and those 
scoring 2 points or more in all categories were classified 
as having low risk of bias.
Two separate sensitivity analyses were done on the 
primary outcome to test the robustness of the results by 
verifying that the overall effect estimates did not change 





43 records identified through other 
sources
19 WHO International 
Clinical Trials Registry 
Platform
12 ClinicalTrials.gov
1 Cochrane Central 
Register of Controlled Trials 
11 reference sections of 
retrieved papers
104 records identified through 
database searching
84 MEDLINE
   7 Scopus
 13 Toxline
50 full-text articles assessed for eligibility
65 excluded based on title or 
abstract
8 studies included in qualitative synthesis
42 excluded as they did not meet 
the eligibility criteria
6 studies included in quantitative synthesis 
(meta-analysis)
2 excluded as no pregnancy 
outcomes were described 
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after removing studies with high risk of bias and studies 
with fewer than 100 participants from the meta­analysis.
The certainty of the evidence was rated for each 
outcome using the GRADE approach.27 Evidence from 
RCTs starts at high quality, whereas evidence from 
observational data is considered low quality. The certainty 
in the evidence can be downgraded for risk of bias, 
imprecision, inconsistency, indirectness, and publication 
bias. Studies can also be upgraded if there was a large 
effect, a dose–response effect, and if all plausible residual 
confounding would reduce a demonstrated effect or 
would suggest a spurious effect if no effect was observed.28
The extracted data were entered and analysed using 
RevMan (version 5.3). The search and analysis protocol 
were registered on PROSPERO in 2016 (CRD42016046914).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
The initial search retrieved 147 records, of which only 
eight (5%) articles met the criteria for qualitative synthesis 
and six (4%) for quantitative analysis. Figure 1 depicts the 
study selection process according to the PRISMA state­
ment for systematic reviews and meta­analysis.29 Despite 
contacting the corresponding authors of two eligible 
studies,30,31 we were unable to retrieve data for the number 
of events in the intervention and control groups needed 
for the meta­analysis and thus only analysed them 
qualitatively. Burnham30 described an RCT to determine 
adverse reactions to ivermectin given annually for treat­
ment of onchocerciasis. Three pregnant women were 
inadvertently treated with ivermectin during the course of 
the trial, whose course of pregnancy and delivery was 
normal and no abnormality was noted in the children. 
Pregnancy outcomes in the control group were not 
described. Yumkella31 studied knowledge, attitudes, and 
practices regarding onchocerciasis with a focus on the 
perceptions of women during mass treatment campaigns 
with ivermectin. After drug distribution, 100 pregnant 
women were interviewed, and 27 reported having been 
inadvertently treated with ivermectin. No further infor­
mation about pregnancy outcomes was provided.
The six studies included for the quantitative analysis 
were published between 1990 and 2008, and were done 
in six African countries: Uganda, Ghana, Cameroon, 
Tanzania, Mali, and Liberia (table 1). They encompassed 
a total of 893 women with 899 pregnancy outcomes; 
496 pregnant women (500 pregnancy outcomes) received 
ivermectin inadvertently during MDA campaigns reported 
in nested case­control studies,13,32–35 and 397 pregnant 
women (399 pregnancy outcomes) purposely received 
ivermectin as part of an open­label RCT.36 The studies 
reported the following serious adverse events during preg­
nancy: spontaneous abortions, stillbirth, and congenital 
anomalies. Other serious adverse events and adverse 
events defined in the protocol were not described in these 
studies and therefore could not be included in the analysis.
97 women were reportedly exposed to ivermectin during 
the first trimester32 and 397 women during the second or 
third trimester.36 The time of exposure of the remaining 
399 women was undefined after review and contact with 
the authors.13,33–35 The control group comprised pregnant 
women in the same population excluded from MDA or 
unexposed to ivermectin during the same period. Two of 
the retrospective case­control studies34,35 nested in the 
MDA campaigns and the RCT36 administered ivermectin 
and albendazole to pregnant women whereas all the other 





















Cameroon Yes, during MDA 
programme
No First trimester* 21/111 53/404 0/111 2/404




Mali Yes, during MDA 
programme
No Unclear 3/82 6/139 0/82 1/139




Ghana Yes, during MDA 
programme
Yes Unclear 2/50 21/293 1/50 5/293




Tanzania Yes, during MDA 
programme
Yes Unclear NA NA 6/54 4/63




Uganda No Yes Second and 
third trimester
4/399 7/438 1/399 1/438




Liberia Yes, during MDA 
programme
No Unclear 5/203 55/1767 5/203 21/1767
Data are n/N, unless otherwise specified. MDA=mass drug administration. NA=not available. *97 of 110 were exposed during the first trimester of pregnancy; the remaining 13 were not specified. These 110 exposures 
generated 111 pregnancy outcomes.
Table 1: Summary of included studies for the quantitative analysis
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studies13,32,33 administered ivermectin alone. Excluded 
studies and rationale for exclusion after abstract or full­
text reading are presented in the appendix (pp 4, 5). 
Additionally, the sources of funding for included studies 
are detailed in the appendix (p 6).
None of the studies scored the maximum score of 
three points for selection bias (table 2). Pregnancy stage 
at time of ivermectin exposure was based on record 
linkage and retrospective self­reports. Contrary to the 
only RCT, none of the observational studies tested for 
pregnancy at time of ivermectin exposure; therefore, 
independent validation was insufficient. The case­
control studies nested in the MDA campaigns were not 
designed to answer whether ivermectin is safe during 
pregnancy, hence comparability between ivermectin­
exposed and control groups was poorly matched for 
important factors likely to bias the primary outcome, 
such as age of the mother, risk behaviour, history of 
pregnancy­related adverse events, distance from the 
participant’s home to a health­care facility, or any other 
important factor. Only Pacque and colleagues13 ensured 
similar age groups were included in both groups at 
the time of analysis, while Makene and colleagues35 
ensured abnormalities such as splenomegaly and 
associated changes commonly expected in areas of high 
endemicity for malaria and other infections were 
common to both groups. Two studies33,34 relied on self­
reports of serious adverse events rather than health 
facility records. The ascertainment of exposure of cases 
and controls was equally poor in all studies. Only one 
study13 reported participant record linkage during MDA 
through a house­to­house census, whereas other studies 
relied on self­reports of drug intake. Overall the risk of 
bias was high because three of the five studies did not 
score on comparability.
The risk of bias for Ndyomugyenyi and colleagues’ 
study36 was assessed separately using the Cochrane risk­
of­bias tool for RCTs.26 The risk of bias was judged as 
high because of an undescribed allocation concealment 
method and the absence of blinding, which might have 
increased performance bias (table 3).
The observational studies reported 31 spontaneous 
abortions and stillbirths from 446 outcomes of preg nan­
cies inadvertently exposed to ivermectin compared with 
135 cases from 2603 control outcomes (OR 1·15, 95% CI 
0·75–1·78; figure 2; table 4). Subgroup analysis on the 
concomitant administration of albendazole and ivermectin 
showed no significant odds of spontaneous abortions and 
stillbirths (0·54, 0·12–2·38; p=0·41) as with ivermectin 
alone (1·24, 0·79–1·94; p=0·36; figure 2). The RCT36 
reported four spontaneous abortions and stillbirths from 
399 pregnancy outcomes after exposure to ivermectin or 
Selection* Comparability† Exposure‡ Risk of bias
Score Notes Score Notes Score Notes
Chippaux 
et al (1993)32
2 Pregnancy tests were not done and therefore no 
independent validation of pregnancy was available
NA Study was not controlled for age, 
history of pregnancy-related 
serious adverse events, or any 
other substantial factor
2 Exposure to ivermectin was self-reported High
Doumbo et 
al (1992)33
2 Pregnancy tests were not done and therefore no 
independent validation of pregnancy was available; 
adverse pregnancy outcomes were self-reported
NA Study was not controlled for age, 
history of pregnancy-related 
serious adverse events, or any 
other substantial factor
2 Exposure to ivermectin was self-reported High
Gyapong et 
al (2003)34
2 Pregnancy tests were not done and therefore no 
independent validation of pregnancy was available
NA Study was not controlled for age, 
history of pregnancy-related 
serious adverse events, or any 
other substantial factor
1 Exposure to ivermectin was self-reported; 
the study reports exposure to albendazole 
or ivermectin during pregnancy, in which 
it is unclear if all cases received ivermectin
High
Makene et al 
(2003)35
2 Pregnancy tests were not done and therefore no 
independent validation of pregnancy was available; 
adverse pregnancy outcomes were self-reported
1 ∙∙ 2 Ascertainment of exposure was not 
described
Moderate
Pacque et al 
(1990)13
2 Pregnancy tests were not done and therefore no 
independent validation of pregnancy was available
1 ∙∙ 3 ∙∙ Moderate
NA=not available. *Maximum score of 4. †Maximum score of 2. ‡Maximum score of 3.
Table 2: Risk of bias assessment of the observational studies using the Newcastle-Ottawa Scale
Risk of bias Support for judgment
Random sequence generation 
and allocation concealment 
(selection bias)
Unclear A random sequence was generated in SPSS; the allocation 
concealment method was not described
Blinding of participants and 
personnel (performance bias)
High The study design was an open-label randomised controlled 
trial
Blinding of outcome 
assessment (detection bias)
Low Severe adverse events are an objective outcome and their 
detection is unlikely to have been affected by no blinding
Incomplete outcome data 
(attrition bias)
Low Loss to follow-up was similar across the different study 
groups, ranging from 26% to 33%
Selective outcome reporting 
(reporting bias)
Unclear A study protocol was not found in any of the clinical trial 
registries; the study was not registered in any clinical trial 
repository
Other bias Low The authors took measures to prevent baseline imbalances 
between study groups
Table 3: Risk of bias assessment of Ndyomugyenyi et al (2008)36 using the Cochrane risk-of-bias tool for 
randomised controlled trials
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ivermectin in combination with albendazole during the 
second and third trimester, compared with seven events 
from 438 pregnancy outcomes in the control group (0·62, 
0·18–2·14; table 5).
Additionally, the observational studies reported 
12 congenital anomalies from 500 pregnancy outcomes 
compared with 33 cases from 2666 control outcomes 
(OR 1·69, 95% CI 0·83–3·41; figure 3; table 4). The 
certainty of this evidence from observational studies 
was assessed as very low using the GRADE approach; 
the details of each component of the assessment are 
provided in the appendix (p 7).
Subgroup analysis on the safety of ivermectin in 
combination with albendazole revealed similar odds of 
congenital anomalies after receiving ivermectin in com­
bi nation with albendazole (OR 1·63, 95% CI 0·53–5·04) 
compared with ivermectin alone (1·72, 0·70–4·24). 
The RCT36 reported only one congenital anomaly from 
399 pregnancy outcomes of women inadvertently exposed 
to ivermectin or ivermectin in combination with alben­
dazole during their second and third gestational 
trimesters as well as one case from 438 outcomes from 
the albendazole group (1·10, 0·07–17·65; table 5). The 
certainty of the evidence from the RCT was assessed 
as very low using the GRADE approach; the details of 
each component of the assessment are provided in the 
appendix (p 8).
Publication bias was not assessed because there were 
less than ten studies included in this systematic review 
and meta­analysis.
Sensitivity analyses were done when possible. After 
excluding studies at high risk of bias32–34 from the meta­
analysis describing the risk of congenital anomalies, 
the overall point estimate did not change significantly 
(from OR 1·69 [95% CI 0·83–3·41] to 2·0 [0·91–4·42]). 
The same analysis was not possible for spontaneous 

























4 3042 446 2603 31 135 1∙15 (0∙75–1∙78)
Congenital 
anomalies
5 3159 500 2666 12 33 1∙69 (0∙83–3∙41)
Data are n unless stated otherwise. All studies were retrospective case-control studies. The number of pregnancy outcomes exceeds the number of pregnant women because 
of several sets of twins.
Table 4: Summary of data from the observational studies measuring serious adverse events in women exposed to ivermectin during pregnancy
Figure 2: Forest plot for risk of spontaneous abortions and stillbirths after exposure to ivermectin during pregnancy compared with no exposure
Evidence is from observational studies. NA=not applicable.
Ivermectin in combination with albendazole
Gyapong et al (2003)34
Subtotal
Heterogeneity: NA
Test for overall effect: Z=0·82, p=0·41
Ivermectin only
Chippaux et al (1993)32
Doumbo et al (1992)33
Pacque et al (1990)13
Subtotal
Heterogeneity: p=0·40, I2=0%
Test for overall effect: Z=0·92, p=0·36
Total
Heterogeneity: p=0·40, I2=0%
Test for overall effect: Z=0·64, p=0·52

















































Odds ratio (95% CI)
Decreased odds Increased odds
0·01 0·1 1 10 100
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abortions and stillbirths because three out of five studies 
were considered to be at high risk of bias. After 
excluding trials with wide confidence intervals and 
low number of events33,34 from the meta­analysis, the 
odds of spontaneous abortions and stillbirths did not 
change significantly (from OR 1·15 [95% CI 0·75–1·78] 
to 1·22 [0·65–2·30]), nor did the odds of congenital 
anomalies (from 1·69 [0·83–3·41] to 12·9 [0·74–4·85]).
Discussion
Although serious adverse events were reported during 
pregnancy in a non­negligible frequency (1·36% in 
observational studies and 0·6% in one RCT), any causal 
relationship between ivermectin administration and the 
unfavourable clinical outcome cannot be easily assessed, 
since the number of recorded exposures is too low to 
achieve statistical power and it is not possible to discard 
selection bias due to absence of blinding and randomised 
controls.
Only eight papers were eligible for inclusion in our 
review. These studies encompass 893 women exposed 
inadvertently to ivermectin during pregnancy; of these, 
only 97 were reportedly exposed during the first trimester. 
Pooled results from all nested retrospective case­control 
studies showed no difference in pregnancy­related serious 
adverse events from inadvertently exposed mothers. 
The only RCT included showed a non­significant effect of 
ivermectin exposure in pregnancy on increased rates of 
abortions, stillbirths, and congenital anomalies. Overall, 
given the small sample, point estimates of serious adverse 
events had wide overlapping CIs crossing the point of no 
effect.
The results of the primary outcomes were graded as 
very low certainty of evidence because of bias generated 























1 832 399 438 4 7 0∙62 (0∙18–2∙14)
Congenital 
anomalies
1 832 399 438 1 1 1∙10 (0∙07–17∙65)
Data are n unless stated otherwise. The number of pregnancy outcomes exceeds the number of pregnant women because of several sets of twins.
Table 5: Summary of data from the single randomised controlled trial measuring serious adverse events in women treated with ivermectin during 
pregnancy
Figure 3: Forest plot for risk of congenital anomalies after exposure to ivermectin during pregnancy compared with no exposure
Evidence is from observational studies.
Ivermectin in combination with albendazole
Gyapong et al (2003)34
Makene et al (2003)35
Subtotal
Heterogeneity: p=0·73, I2=0% 
Test for overall effect: Z=0·85, p=0·39
Ivermectin only
Chippaux et al (1993)32
Doumbo et al (1992)33
Pacque et al 1990)13
Subtotal
Heterogeneity: p=0·62, I2=0%
Test for overall effect: Z=1·18, p=0·24
Total
Heterogeneity: p=0·90, I2=0%
Test for overall effect: Z=1·46, p=0·15
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by improper study designs and lack of power leading to 
a high degree of imprecision. The review authors 
downgraded observational studies mainly because of 
comparability bias, as studies were unable to ensure 
that the pregnant women between study groups were 
com parable in regard to key risk factors such as age 
and history of serious adverse events during pregnancy. 
The lack of comparability is unsurprising given that 
these studies were not designed as case­control studies to 
address safety of ivermectin during pregnancy but were 
reports of observations following MDA programmes. 
Evidence from the RCT was also rated as very low 
certainty of evidence, as the study was not blinded (risk 
of performance bias) and we could not clearly assess the 
allocation concealment method (risk of selection bias). 
Additionally, all studies were underpowered, estimates 
had wide confidence intervals, very few events were 
recorded, and the point estimate included the point of no 
effect. Importantly, given that ivermectin exposure was 
determined based on record linkage and retrospective 
self­reports, the potential role of recall bias cannot be 
determined.
The included studies were not adequately designed to 
address the question posed in this review of whether 
ivermectin exposure could negatively affect pregnancy 
outcomes. During the first trimester, women are less 
likely to reveal their state because of social risk, desire 
for privacy, and doubts, and hence are potentially more 
exposed to inadvertent treatment. However, fewer than 
100 known exposures to ivermectin in the first trimester 
were identified and included in this meta­analysis.
Given the absence of evidence to support clinical trials 
with ivermectin in pregnancy, plausible next steps could 
include reproductive toxicological studies in primates. 
Another readily available option is an open data repository 
of inadvertent drug exposures during pregnancy. We 
estimate that given a baseline population rate of congenital 
anomalies of 23·9 per 1000 births,37 a sample of at least 
72 000 exposures is needed to detect a 10% increase due to 
ivermectin (80% power at 5% significance). For stillbirths, 
this number increases to 92 000 given a baseline rate of 
18·3 per 1000 births.38 These numbers, although very 
large, do still appear feasible if one considers that more 
than 300 million people are treated every year in the 
context of onchocerciasis and lymphatic filariasis elimin­
ation programmes. However, despite large­scale MDA 
with ivermectin over the past 30 years, there are very few 
records of well documented outcomes after inadvertent 
exposure to ivermectin in pregnancy. These available 
records are from African populations, extracted from 
underpowered studies with a design not intended for 
this purpose. Given the frequency and distribution of 
MDA programmes of ivermectin, it is remarkable that no 
reports have been published in the past 10 years. This study 
cannot draw evidence­based conclusions on whether or 
not there are deleterious effects of oral ivermectin during 
pregnancy. Further high­quality evidence supporting the 
safety of ivermectin administration in this particular 
vulnerable group is imperative.
This review was limited by the small number of 
published reports available and the fact that all included 
studies were done more than 10 years ago with some 
going back almost 30 years; only a few of the corres­
ponding authors contacted were able to respond to 
requests for additional details.
When ivermectin is used in MDA for onchocerciasis 
control, population coverage is a key factor for effec­
tiveness;39 a similar community effect is expected for 
the proposed new indication to reduce malaria trans­
mission.40,41 Reproductive toxicological studies of primates 
might provide further insight on the safety of ivermectin 
during pregnancy in addition to the development of an 
open and high­quality data repository on the outcome of 
inadvertently exposed pregnancies.
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